arrow
J

John B. Porter

copenhagen university hospital
H指数:76
被引数:2.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Efficacy and safety of mitapivat in adults with transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE-T): a double-blind, randomised, multicentre, placebo-controlled, phase 3trial

米塔匹泛在依赖输血的α-地中海贫血或β-地中海贫血成人中的有效性和安全性(ENERGIZE-T):一项双盲、随机、多中心、安慰剂对照、III期临床试验

2026-09-121
PRE
Achieving clinically meaningful changes in haemoglobin levels in patients with non-transfusion-dependent β-thalassaemia treated with luspatercept: A post hoc analysis of the phase 2 BEYOND trial

通过Luspatercept治疗非输血依赖性β-地中海贫血患者实现血红蛋白水平的临床显著变化:一项BEYOND试验2期研究的事后分析

2025-10-260
PRE
Efficacy and safety of luspatercept in non-transfusion-dependent β-thalassemia: long-term results from the BEYOND study

luspaterecpt 在非输血依赖性β-地中海贫血中的有效性和安全性:BEYOND研究的长期能力结果

2025-09-010
OAAI
Modified-release hydrocortisone is associated with lower plasma renin activity in patients with salt-wasting congenital adrenal hyperplasia
2023-01-196
OA
Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial
2022-10-0131
PRE
Betibeglogene Autotemcel Gene Therapy for Non-β0/β0 Genotype β-Thalassemia

Betibeglogene Autotemcel基因治疗非 β0/β0基因型 β 地中海贫血

2022-02-03123
OA